Lamattina John L
- SEC CIK
- 0001216074
In the past year, 3 open-market sale filings worth $2.44M and no purchases.
Current role at each company
- LGND Ligand Pharmaceuticals IncDirectoras of Jun 12, 2026
- IMNM Immunome Inc.Directoras of Jun 12, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $2.44M
- 3 filings
- Net
- −$2.44M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Lamattina John L as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
LGND Ligand Pharmaceuticals Inc
Director5 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 12, 2026 (view filing) | Jun 10 | 2 days | Lamattina John LDirector | SSale | −4.59K | $250.88 | −$1.15M | −14.5%27.0K after | 4 lots |
| Mar 31, 2026 (view filing) | Mar 6 | 25 daysLate | Lamattina John LDirector | SSale | −2.16K | $200.76 | −$433.8K | −6.6%30.7K after | |
| Nov 12, 2025 (view filing) | Nov 7 | 5 days | Lamattina John LDirector | SSale | −4.18K | $205.45 | −$858.6K | −12.0%30.7K after | 2 lots |
| Dec 2, 2024 (view filing) | Nov 27 | 5 days | Lamattina John LDirector | SSale | −2.41K | $123.65 | −$297.5K | −7.5%29.5K after | |
| Nov 17, 2021 (view filing) | Nov 16 | 1 day | Lamattina John LDirector | SSale | −4.83K | $161.86 | −$782.6K | −16.0%25.4K after |